Sermorelin Dosage: Doses Studied, Units and Chart
What doses of Sermorelin have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 6 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- Vial sizes sold
- 2 mg, 5 mg, 9 mg, 15 mg
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 0.5 mg (low) and 1 mg (high) GHRH-(1-29) | twice daily · subcutaneous · 14 days per dose, with a 14-day washout | Human RCTn = 10 | The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| 100 mcg each of GHRP-6, GHRP-2 and sermorelin | three times daily · not stated · mean 134 days | Human observationaln = 14 | American journal of men's health 2017, PMID 28830317 |
| 2 mg GHRH (1-29) | nightly self-injection · subcutaneous · 6 weeks | Human uncontrolled trialn = 11 | Metabolism: clinical and experimental 1997, PMID 9005976 |
| 30 micrograms/kg/day GHRH-(1-29) | once daily at bedtime · subcutaneous · up to 1 yr | Human uncontrolled trialn = 110 | The Journal of clinical endocrinology and metabolism 1996, PMID 8772599 |
| 30 micrograms/kg | once daily · subcutaneous · 12 to 24 months | Human uncontrolled trialn = 16 | The Journal of pediatric endocrinology 1994, PMID 7735367 |
| 30 microg/kg bodyweight | once daily at bedtime · subcutaneous | Review | BioDrugs 1999, PMID 18031173 |
Dose to syringe units
For a 5 mg vial mixed with 2 mL of bacteriostatic water (2.5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 100 mcg
- 4 u
- 200 mcg
- 8 u
- 300 mcg
- 12 u
- 400 mcg
- 16 u
- 500 mcg
- 20 u
- 750 mcg
- 30 u
Before anyone considers it
- Sermorelin is not FDA approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
A daily schedule with a year of follow-up is documented in children
A multicentre study treated prepubertal growth-hormone-deficient children with 30 micrograms/kg per day of GHRH-(1-29) at bedtime for up to 1 yr.[6]
A review of sermorelin in children describes once-daily subcutaneous 30 microg/kg at bedtime as effective in some prepubertal children with idiopathic growth hormone deficiency.[7]
A separate intravenous 1 microg/kg amount is the diagnostic test dose described in that review, a different purpose from treatment.[7]
Sermorelin amounts used in the adult studies (men)
In old men, 0.5 mg (low) and 1 mg (high) of GHRH-(1-29) were each injected subcutaneously twice daily for 14 days, with a 14-day washout between.[3]
Only the high dose produced significant differences from old-men baseline values in 24-h GH and IGF-I.[3]
In a separate study, eleven older men self-injected 2 mg GHRH nightly for 6 weeks.[5]
Regulatory context
The only Drugs@FDA record for sermorelin is a discontinued product (Geref), so no currently marketed US label gives a dose.[13]
Common questions
How many units is 300 mcg of Sermorelin?
It depends on the water added. A 5 mg vial with 2 mL of water gives 2.5 mg/mL, so 300 mcg is 12 units on a U-100 syringe. Use the calculator for other mixes.
Is Sermorelin FDA approved?
No. Sermorelin is not FDA approved for any use.
What is the standard sermorelin dosage?
In the studies cited here, the daily amount in growth-hormone-deficient children was 30 micrograms/kg at bedtime. The adult studies used fixed milligram amounts.[6]
Is there a sermorelin dosage for women?
No. The adult studies found here enrolled men, so none reports a dosing arm for women.[3]
What are the studied sermorelin amounts in units and mL?
For illustration only, if a 5 mg vial were mixed with 2 mL (2.5 mg/mL), the 0.5 mg, 1 mg and 2 mg study amounts would come to 0.2 mL (20 units), 0.4 mL (40 units) and 0.8 mL (80 units) on a U-100 syringe. These are the amounts the studies used, not a recommendation.
Calculated from concentration mg per mL 2.5; study amounts mg 0.5, 1, 2; units per mL u100 100. Formula: mL = mg / 2.5; units = mL x 100: 0.5/2.5 = 0.2 mL = 20 u; 1/2.5 = 0.4 mL = 40 u; 2/2.5 = 0.8 mL = 80 u
What sermorelin dose was studied in children?
Prepubertal children with growth hormone deficiency received 30 micrograms/kg once a day under the skin at bedtime for up to 1 yr. The aim was treating GH deficiency, not height in general.[6]
Was 2 mg (2000 mcg) of sermorelin used in a study?
Yes. The nightly 2 mg amount in the eleven-man older-men study equals 2000 mcg, since each mg is 1000 mcg.
Calculated from study dose mg 2; mcg per mg 1000. Formula: 2 mg x 1000 mcg/mg = 2000 mcg
How often was sermorelin given in studies: once or twice a day?
It depended on the study. Children had a single bedtime injection, and the older-men studies used twice-daily injections in one and single nightly injections in the other.[3]
More on Sermorelin
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 4Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 5Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 6Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 7Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999PMID 18031173Accessed 2 Oct 2026
- 8PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. Venezuelan Collaborative Study Group.The Journal of pediatric endocrinology · 1994PMID 7735367Accessed 11 Oct 2026
- 12PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 13Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.